The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Triggering global regulatory submissions this year for the treatment of obesity
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Subscribe To Our Newsletter & Stay Updated
